Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
Day One Biopharmaceuticals (DAWN) has announced it will host a conference call and webcast on Tuesday, February 25, 2025, at 4:30 p.m. ET to discuss its fourth quarter and full-year 2024 financial results and corporate progress. The live audio webcast will be available on the company's Investors & Media page, with a replay accessible for 30 days following the event in the Events & Presentations section.
Day One Biopharmaceuticals (DAWN) ha annunciato che ospiterà una conferenza telefonica e una trasmissione in webcast martedì 25 febbraio 2025, alle 16:30 ET per discutere i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 e i progressi aziendali. La trasmissione audio in diretta sarà disponibile nella pagina Investitori & Media dell'azienda, con una replica accessibile per 30 giorni dopo l'evento nella sezione Eventi & Presentazioni.
Day One Biopharmaceuticals (DAWN) ha anunciado que llevará a cabo una conferencia telefónica y una retransmisión en webcast el martes 25 de febrero de 2025, a las 4:30 p.m. ET para discutir sus resultados financieros del cuarto trimestre y del año completo 2024 y avances corporativos. La retransmisión de audio en vivo estará disponible en la página de Inversores y Medios de la empresa, con una repetición accesible durante 30 días después del evento en la sección de Eventos y Presentaciones.
데이 원 바이오파마 수티컬스(DAWN)는 2025년 2월 25일 화요일 오후 4시 30분 ET에 전화 회의 및 웹캐스트를 개최하여 2024년 4분기 및 전체 연도 재무 결과와 회사 진전을 논의할 것이라고 발표했습니다. 생중계 오디오 웹캐스트는 회사의 투자자 및 미디어 페이지에서 제공되며, 이벤트 & 프레젠테이션 섹션에서 이벤트 후 30일 동안 재생할 수 있습니다.
Day One Biopharmaceuticals (DAWN) a annoncé qu'il tiendra une conférence téléphonique et un webcast mardi 25 février 2025 à 16h30 ET pour discuter de ses résultats financiers du quatrième trimestre et de l'année entière 2024 ainsi que des progrès de l'entreprise. Le webcast audio en direct sera disponible sur la page Investisseurs & Médias de l'entreprise, avec une rediffusion accessible pendant 30 jours suivant l'événement dans la section Événements & Présentations.
Day One Biopharmaceuticals (DAWN) hat angekündigt, dass am Dienstag, den 25. Februar 2025, um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden werden, um über die Finanzergebnisse des vierten Quartals und des Gesamtjahres 2024 sowie den Fortschritt des Unternehmens zu berichten. Der Live-Audio-Webcast wird auf der Seite Investoren & Medien des Unternehmens verfügbar sein, mit einer Wiederholung, die 30 Tage nach der Veranstaltung im Bereich Veranstaltungen & Präsentationen zugänglich ist.
- None.
- None.
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2024.
Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days following the event.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage company focused on advancing first- or best-in-class medicines for childhood and adult diseases with equal intensity. We were founded to address the lack of new therapies resulting from the traditional drug development model, which has left children with cancer and their families waiting too long for new treatments.
At Day One, we aim to identify and develop breakthrough medicines with the goal of improving the outcomes and life trajectories of patients of any age facing serious diseases — starting from Day One. Our “search & development” strategy enables us to find, acquire, and develop potential best-or first-in-class programs with the goal of introducing new medicines that will make a real difference in the treatment of children and adults.
Day One’s pipeline includes tovorafenib (OJEMDA™), DAY301 and a VRK1 inhibitor program. The Company is based in Brisbane, California and can be found online at www.dayonebio.com, LinkedIn or X.
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When will Day One Biopharmaceuticals (DAWN) report Q4 and full-year 2024 earnings?
How can investors access DAWN's Q4 2024 earnings call?
How long will DAWN's Q4 2024 earnings call replay be available?
What will be discussed in Day One Biopharmaceuticals' (DAWN) upcoming earnings call?
